{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:21:38Z","timestamp":1790112098886,"version":"4.0.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004099","name":"French League against Cancer","doi-asserted-by":"publisher","award":["PRE2018.LCC\/AF"],"award-info":[{"award-number":["PRE2018.LCC\/AF"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"French National Institute of Health and Medical Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mutuelle G\u00e9n\u00e9rale de l\u2019Education Nationale"},{"name":"Gustave Roussy Institute"},{"DOI":"10.13039\/501100004099","name":"French League against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-10-COHO-0006"],"award-info":[{"award-number":["ANR-10-COHO-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Ministry of Higher Education, Research and Innovation","award":["#2103 586016"],"award-info":[{"award-number":["#2103 586016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Epidemiological studies have found that menopausal hormone therapy (MHT) use is associated with an increased ovarian cancer risk. However, whether different MHT types confer the same level of risk is unclear. We estimated the associations between different MHT types and the risk of ovarian cancer in a prospective cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study population included 75\u200a606 postmenopausal women from the E3N cohort. Exposure to MHT was identified from self-reports in biennial questionnaires between 1992 and 2004 and from drug claim data matched to the cohort between 2004 and 2014. Hazard ratios and 95% confidence intervals (CIs) of ovarian cancer were estimated using multivariable Cox proportional hazards models with MHT as a time-varying exposure. Tests of statistical significance were 2-sided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over an average 15.3\u2009years follow-up, 416 ovarian cancers were diagnosed. Hazard ratios of ovarian cancer associated with ever use of estrogens combined with progesterone or dydrogesterone and ever use of estrogens combined with other progestagen were equal to 1.28 (95% CI = 1.04 to 1.57) and 0.81 (95% CI = 0.65 to 1.00), respectively (Phomogeneity\u2009=\u2009.003), compared with never use. The hazard ratio for unopposed estrogen use was 1.09 (95% CI = 0.82 to 1.46). We found no trend according to duration of use or time since last use except for estrogens combined with progesterone or dydrogesterone, which showed decreasing risk with increasing time since last use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Different MHT types may impact ovarian cancer risk differentially. The possibility that MHT containing progestagens other than progesterone or dydrogesterone may confer some protection should be evaluated in other epidemiological studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djad035","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T19:06:15Z","timestamp":1677006375000},"page":"671-679","source":"Crossref","is-referenced-by-count":13,"title":["Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-3439","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Fournier","sequence":"first","affiliation":[{"name":"\u201cExposome, Heredity, Cancer and Health\u201d Team, Centre for Epidemiology and Population Health (CESP UMR 1018), Universit\u00e9 Paris-Saclay, Inserm, Institut Gustave Roussy , Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-3120","authenticated-orcid":false,"given":"Manon","family":"Cairat","sequence":"additional","affiliation":[{"name":"\u201cExposome, Heredity, Cancer and Health\u201d Team, Centre for Epidemiology and Population Health (CESP UMR 1018), Universit\u00e9 Paris-Saclay, Inserm, Institut Gustave Roussy , Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-419X","authenticated-orcid":false,"given":"Gianluca","family":"Severi","sequence":"additional","affiliation":[{"name":"\u201cExposome, Heredity, Cancer and Health\u201d Team, Centre for Epidemiology and Population Health (CESP UMR 1018), Universit\u00e9 Paris-Saclay, Inserm, Institut Gustave Roussy , Villejuif, France"},{"name":"Department of Statistics, Computer Science and Applications \u201cG. Parenti\u201d, University of Florence , Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-6761","authenticated-orcid":false,"given":"Marc J","family":"Gunter","sequence":"additional","affiliation":[{"name":"Nutrition and Metabolism Branch, International Agency for Research on Cancer , Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6846-1204","authenticated-orcid":false,"given":"Sabina","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Nutrition and Metabolism Branch, International Agency for Research on Cancer , Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2716-5748","authenticated-orcid":false,"given":"Laure","family":"Dossus","sequence":"additional","affiliation":[{"name":"Nutrition and Metabolism Branch, International Agency for Research on Cancer , Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2023060809402664800_djad035-B1","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans;","year":"2008"},{"issue":"10204","key":"2023060809402664800_djad035-B2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2023060809402664800_djad035-B3","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3390\/cancers12082195","article-title":"Menopausal hormone therapy and risk of endometrial cancer: a systematic review","volume":"12","author":"Tempfer","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2023060809402664800_djad035-B4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/GME.0000000000000550","article-title":"Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis","volume":"23","author":"Shi","year":"2016","journal-title":"Menopause"},{"issue":"1","key":"2023060809402664800_djad035-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"issue":"3","key":"2023060809402664800_djad035-B6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2023060809402664800_djad035-B7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American Menopause Society","volume":"24","author":"NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause."},{"issue":"1","key":"2023060809402664800_djad035-B8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal symptoms","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"7","key":"2023060809402664800_djad035-B9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4158\/EP171828.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause \u2013 2017 update","volume":"23","author":"Cobin","year":"2017","journal-title":"Endocr Pract"},{"issue":"9","key":"2023060809402664800_djad035-B10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1701-2163(15)30487-4","article-title":"Managing menopause","volume":"36","author":"Reid","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"issue":"8","key":"2023060809402664800_djad035-B11","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamainternmed.2016.2761","article-title":"Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline","volume":"176","author":"Lumsden","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2023060809402664800_djad035-B12","author":"NHS Business Services Authority. 2022"},{"issue":"23","key":"2023060809402664800_djad035-B13","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/jnci\/90.23.1774","article-title":"Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone","volume":"90","author":"Risch","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2023060809402664800_djad035-B14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fendo.2014.00192","article-title":"Estrogen biosynthesis and action in ovarian cancer","volume":"5","author":"Mungenast","year":"2014","journal-title":"Front Endocrinol"},{"issue":"8","key":"2023060809402664800_djad035-B15","doi-asserted-by":"crossref","first-page":"bvac100","DOI":"10.1210\/jendso\/bvac100","article-title":"Investigating the effect of estradiol levels on the risk of breast, endometrial, and Ovarian cancer","volume":"6","author":"Johansson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"2023060809402664800_djad035-B16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7827-1-73","article-title":"Estrogen, progesterone and epithelial ovarian cancer","volume":"1","author":"Ho","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"issue":"6","key":"2023060809402664800_djad035-B17","doi-asserted-by":"crossref","first-page":"R255","DOI":"10.1530\/ERC-12-0175","article-title":"Hormone response in ovarian cancer: time to reconsider as a clinical target?","volume":"19","author":"Modugno","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2023060809402664800_djad035-B18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.23956","article-title":"Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin","volume":"115","author":"Pearce","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"2023060809402664800_djad035-B19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/humupd\/dmm012","article-title":"Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis","volume":"13","author":"Greiser","year":"2007","journal-title":"Hum Reprod Update"},{"issue":"3","key":"2023060809402664800_djad035-B20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ygyno.2007.12.003","article-title":"Hormone replacement therapy and ovarian cancer risk: a meta-analysis","volume":"108","author":"Zhou","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"9980","key":"2023060809402664800_djad035-B21","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"2023060809402664800_djad035-B22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(05)70273-4","article-title":"Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023060809402664800_djad035-B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-014-2934-6","article-title":"Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort","volume":"145","author":"Fournier","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"2023060809402664800_djad035-B24","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwu146","article-title":"Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008","volume":"180","author":"Fournier","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2023060809402664800_djad035-B25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ije\/dyu184","article-title":"Cohort profile: the French E3N Cohort Study","volume":"44","author":"Clavel-Chapelon","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"24","key":"2023060809402664800_djad035-B26","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/sim.2098","article-title":"Choice of time-scale in Cox\u2019s model analysis of epidemiologic cohort data: a simulation study","volume":"23","author":"Thi\u00e9baut","year":"2004","journal-title":"Stat Med"},{"issue":"2","key":"2023060809402664800_djad035-B27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.4145","article-title":"New use of prescription drugs prior to a cancer diagnosis","volume":"26","author":"Potteg\u00e5rd","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2023060809402664800_djad035-B28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/AOG.0000000000001387","article-title":"Association between menopausal estrogen-only therapy and ovarian carcinoma risk","volume":"127","author":"Lee","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2023060809402664800_djad035-B29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10552-011-9782-z","article-title":"Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition","volume":"22","author":"Tsilidis","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"1","key":"2023060809402664800_djad035-B30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/13697137.2012.663818","article-title":"Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy \u2013 a nationwide study","volume":"16","author":"Koskela-Niska","year":"2013","journal-title":"Climacteric"},{"issue":"7","key":"2023060809402664800_djad035-B31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jnci\/94.7.497","article-title":"Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women","volume":"94","author":"Riman","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2023060809402664800_djad035-B32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.32706","article-title":"Menopausal hormone therapy treatment options and ovarian cancer risk: a Swedish prospective population-based matched-cohort study","volume":"147","author":"Simin","year":"2020","journal-title":"Int J Cancer"},{"issue":"20","key":"2023060809402664800_djad035-B33","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/archinte.164.20.2253","article-title":"Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer","volume":"164","author":"Glud","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"2023060809402664800_djad035-B34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jama.2009.1052","article-title":"Hormone therapy and ovarian cancer","volume":"302","author":"M\u00f8rch","year":"2009","journal-title":"JAMA"},{"issue":"9574","key":"2023060809402664800_djad035-B35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2023060809402664800_djad035-B36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.fertnstert.2004.03.013","article-title":"Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study","volume":"82","author":"Pike","year":"2004","journal-title":"Fertil Steril"},{"issue":"1","key":"2023060809402664800_djad035-B37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ajog.2004.11.013","article-title":"Menopausal hormones and risk of ovarian cancer","volume":"193","author":"Moorman","year":"2005","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"2023060809402664800_djad035-B38","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1158\/1055-9965.EPI-07-0550","article-title":"Menopausal hormone therapy and risk of epithelial ovarian cancer","volume":"16","author":"Rossing","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"1","key":"2023060809402664800_djad035-B39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.bjc.6603527","article-title":"A prospective study of postmenopausal hormone use and ovarian cancer risk","volume":"96","author":"Danforth","year":"2007","journal-title":"Br J Cancer"},{"issue":"6","key":"2023060809402664800_djad035-B40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10552-008-9125-x","article-title":"Hormone therapy and ovarian cancer: incidence and survival","volume":"19","author":"Wernli","year":"2008","journal-title":"Cancer Causes Control"},{"issue":"12","key":"2023060809402664800_djad035-B41","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1002\/ijc.25515","article-title":"Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen","volume":"127","author":"Hildebrand","year":"2010","journal-title":"Int J Cancer"},{"issue":"3","key":"2023060809402664800_djad035-B42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/EDE.0000000000001175","article-title":"Estrogen plus progestin hormone therapy and ovarian cancer: a complicated relationship explored","volume":"31","author":"Lee","year":"2020","journal-title":"Epidemiology"},{"issue":"1","key":"2023060809402664800_djad035-B43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/1055-9965.98.14.1","article-title":"Endogenous hormones and ovarian cancer: epidemiology and current hypotheses","volume":"14","author":"Lukanova","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2023060809402664800_djad035-B44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"issue":"1","key":"2023060809402664800_djad035-B45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2023060809402664800_djad035-B46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/13595220152601837","article-title":"Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses","volume":"6","author":"Banks","year":"2001","journal-title":"J Epidemiol Biostat"},{"issue":"2","key":"2023060809402664800_djad035-B47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/gme.0b013e3181334b6c","article-title":"Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study","volume":"15","author":"Sandini","year":"2008","journal-title":"Menopause"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djad035\/49577480\/djad035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/6\/671\/50523446\/djad035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/6\/671\/50523446\/djad035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:45:41Z","timestamp":1686217541000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/115\/6\/671\/7049521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,2,21]]},"published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djad035","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,2,21]]}}}